NASDAQ:APM
Aptorum Group Limited Class A Stock News
$5.10
+0.400 (+8.51%)
At Close: May 16, 2024
Aptorum Stock (APM): Why The Price Surged Today
08:55pm, Thursday, 20'th Jan 2022
The stock price of Aptorum Group Ltd (NASDAQ: APM) increased 38.52% today. This is why it happened.
Thinking about buying stock in Aptorum Group, Ford Motor, American Airlines, Luminar Technologies, or Plug Power?
04:10pm, Thursday, 20'th Jan 2022 Benzinga
NEW YORK , Jan. 20, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APM, F, AAL, LAZR, and PLUG. Full story available on Benzinga.com
Aptorum Shares Rise After FDA Orphan Drug Tag For Repurposed Compound For Pediatric Cancer
01:47pm, Thursday, 20'th Jan 2022 Benzinga
The FDA has granted Orphan Drug Designation to Aptorum Group Limited (NASDAQ: APM ) SACT-1, a repurposed small molecule compound for Neuroblastoma. Aptorum Group plans to file an Investigational New Drug Application (IND) to commence a Phase 1b/2a trial … Full story available on Benzinga.com
Aptorum soars on FDAs Orphan Drug Designation for Neuroblastoma candidate
01:22pm, Thursday, 20'th Jan 2022 Seeking Alpha
Nano-cap biotech Aptorum Group (APTM) has added ~19.7% on above-average volume in the pre-market after announcing that the FDA granted it the Orphan Drug Designation to SACT-1, a
Aptorum Group Limited Announces Results of 2021 Annual General Meeting of Shareholders
01:00pm, Friday, 03'rd Dec 2021 Kwhen FinanceAptorum Group Limited Interview to Air on Bloomberg U.S.
08:00am, Friday, 15'th Oct 2021
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM), a clinical stage biopharmaceutical company focused on novel
Aptorum To Start Testing SACT-1 In Neuroblastoma Patients
09:26am, Wednesday, 15'th Sep 2021
The FDA has signed off Aptorum Group Limited's (NASDAQ: APM) IND application to initiate clinical trials of SACT-1 for neuroblastoma. The IND-opening trial is a bioavailability/food effect study th
Aptorum Group Announces Further Positive Interim Results of the Phase 1 Clinical Trial of ALS-4 Targeting Staphylococcus aureus
08:00am, Monday, 12'th Jul 2021
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #MRSA--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical
3 Penny Stocks on Reddit Making Big Waves Right Now
05:24pm, Monday, 24'th May 2021
Which Reddit penny stocks are investors watching right now? Check these 3 out The post 3 Penny Stocks on Reddit Making Big Waves Right Now appeared first on Penny Stocks to Buy, Picks, News and Inform
APM Stock: Over 4% Increase Pre-Market Explanation
07:41am, Thursday, 22'nd Apr 2021
The stock price of Aptorum Group Ltd (NASDAQ: APM) increased by over 4% pre-market. This is why it happened.
APM Stock: 9 Things to Know About Aptorum as Shares Fly on Staph Infection Drug News
10:59am, Wednesday, 20'th Jan 2021
Aptorum (APM) stock is on the rise Wednesday after announcing approval to move forward with a clinical trial of its staph infection drug. The post APM Stock: 9 Things to Know About Aptorum as Shares F
APM Stock Price Increases Over 64% Pre-Market: Why It Happened
08:29am, Wednesday, 20'th Jan 2021
The stock price of Aptorum Group Ltd (NASDAQ: APM) is trading at over 64% pre-market. This is why it happened.
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #CTAsubmission--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical compa
Aptorum Group Limited 2020 Q2 - Results - Earnings Call Presentation
02:42pm, Wednesday, 02'nd Sep 2020
The following slide deck was published by Aptorum Group Limited in conjunction with their 2020 Q2 earnings call.
